P4ha1 may also be a potential biomarker in human atrial fibrillation [49] since hypoxia-induced endothelial P4ha1 overexpression has been reported to enhance angiogenesis by promoting glycolytic metabolism reprogramming through the P4ha1/α-ketoglutarate (α-KG)/ten-eleven translocation 2 (Tet2)/fructose-1,6-biphosphatase (Fbp1) promoter pathway, leading to decreased Fbp1, and enhanced glycolytic metabolism, suggesting its therapeutic potential for post-ischemic tissue repair [50]. The gene discussed is FBP1; the disease is atrial fibrillation.